Respuesta clínica completa postneoadyuvancia en cáncer de recto estadio III: observación o cirugía

  • Pilar Adriana Torres Mesa Instituto Nacional de Cancerología
Palabras clave: Cáncer de recto, respuesta clínica completa, manejo no quirúrgico, terapia neoadyuvante

Resumen

La respuesta clínica completa posterior a la terapia neoadyuvante del cáncer localmente avanzado de recto, se ha considerado suficiente para la implementación de una estrategia no quirúrgica, de observación y seguimiento por algunos autores. El manejo estándar de esta patología es la realización de manejo quirúrgico oncológico radical del tumor primario, 6 a 10 semanas posterior a la finalización de la neoadyuvancia. En esta revisión se exponen los pros y contras de cada propuesta y se describen las implicaciones y recomendaciones de cada alternativa de manejo

Descargas

La descarga de datos todavía no está disponible.

Biografía del autor/a

Pilar Adriana Torres Mesa, Instituto Nacional de Cancerología

Fellow Cirugía Gastrointestinal Oncológica y Endoscopia Digestiva. Instituto Nacional de Cancerología, Universidad Militar Nueva Granada. Bogotá, Colombia. 

Referencias bibliográficas

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. Ca Cancer J Clin 2013; 63: 11-30.

Instituto Nacional de Cancerología E.S.E. Anuarios estadísticos 2003 - 2011. Bogotá.

Piñeros M, Pardo C, Gamboa O, et al. Atlas de mortalidad por cáncer en Colombia, tercera edición. Bogotá, 2010. Instituto Nacional de Cancerología E.S.E; Instituto Geográfico Agustín Codazzi.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Rectal Cancer, Version 2.2014. URL: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.

Van de Velde CJ, Boelens PG, Borras JM, et al. EURECCA colorectal: Multidisciplinary management: European consensus conference Colon & Rectum. Eur J Cancer 2014; 50(1): 1.e1-1.e34.

Meredith KL, Hoffe SE, Shibata D. The multidisciplinary management of rectal cancer. Surg Clin N Am 2009; 89: 177-215.

Glynne-Jones R, Kronfli M. Locally advanced rectal cancer: A comparison of management strategies. Drugs 2011; 71(9): 1153-1177.

Valentini V, Beets-Tan R, Borras JM, et al. Evidence and research in rectal cancer. Radiotherapy and Oncology 2008; 87: 449-474.

McCarthy K, Pearson K, Fulton R, Hewitt J. Quimiorradiación preoperatoria para el cáncer rectal localmente avanzado no metastásico. Cochrane Database of Systematic Reviews 2012 Issue 12. Art. No.: CD008368.

Jeong WL, Jong HL, Jun-Gi K, et al. Comparison between preoperative and postoperative concurrent chemoradiotherapy for rectal cancer: an institutional analysis. Radiat Oncol J 2013; 31(3): 155-161.

Weisser M, Beets-Tan R and Beets G. Management of complete response after chemoradiation in rectal cancer. Surg Oncol Clin N Am 2014; 23 (1): 113-125.

Habr-Gama A, M.D., Perez RO, Nadalin W. Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. J Gastrointest Surg 2005; 9: 90-101.

Glynne-Jones R, Wallace M, Livingstone JIL, et al. Complete clinical response after preoperative chemoradiation in rectal cancer: Is a “wait and see” policy justified? Diseases of the Colon & Rectum 2008; 51: 10-20.

Habr-Gama A, de Souza PM, Ribeiro U, et al. Low rectal cancer: impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum 1998; 41: 1087-1096.

Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative Treatment for Stage 0 Distal Rectal Cancer Following Chemoradiation Therapy. Long-term Results. Ann Surg 2004; 240:711–718.

Habr-Gama A, Perez RO, Nadalin W. Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. J Gastrointest Surg 2005; 9: 90-101.

Habr-Gama A. Assessment and management of the complete clinical response of rectal cancer to chemoradiotherapy. Colorectal Disease 2006; 8(3): 21-24.

Habr-Gama A, Perez RO, Proscurshim I, et al. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg 2006; 10: 1319-1329.

Habr-Gama A, Perez RO, São Julião GP, et al. Nonoperative approaches to rectal cancer: A critical evaluation. Semin Radiat Oncol 2011; 21: 234-239.

Habr-Gama A, Perez RO, Wynn G, et al. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: Characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum 2010; 53: 1692-1698.

Habr-Gama A, Perez R, Proscurshim I, et al. Complete clinical response after neoadjuvant chemoradiation for distal rectal cancer. Surg Oncol Clin N Am 2010; 19: 829-845.

Perez RO, Habr-Gama A, Pereira GV, et al. Role of biopsies in patients with residual rectal cáncer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer? Colorectal Disease 2011; 14: 714-720.

Perez RO, Habr-Gama A, Sao Juliao GP, et al. Optimal Timing for Assessment of Tumor Response to Neoadjuvant Chemoradiation in Patients with Rectal Cancer: Do All Patients Benefit from Waiting Longer than 6 Weeks? Int J Radiat Oncol Biol Phys 2012; 84(5): 1159-1165.

Perez RO, Habr-Gama A, Lynn PB, et al. Transanal Endoscopic Microsurgery for Residual Rectal Cancer (ypT0-2) Following Neoadjuvant Chemoradiation Therapy: Another Word of Caution. Dis Colon Rectum 2013; 56: 6-13.

Habr-Gama A, Sabbaga J, Gama-Rodrigues J, et al. Watch and Wait Approach Following Extended Neoadjuvant Chemoradiation for Distal Rectal Cancer: Are We Getting Closer to Anal Cancer Management? Dis Colon Rectum 2013; 56: 1109-1117.

Bonnetain F, Bosset JF, Gerard JP, et al. What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question?. European Journal of Cancer 2012; 48 (12): 1781-1790.

O’Neill BP, Brown G, Heald RJ. Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. Lancet Oncol 2007; 8: 625-633.

De Nardi P, Carvello M. How reliable is current imaging in restaging rectal cancer after neoadjuvant therapy? World J Gastroenterol 2013; 19(36): 5964-5972.

Hughes R, Harrison M, Glynne-Jones R. Could a wait and see policy be justified in T3/4 rectal cancers after chemo-radiotherapy? Acta Oncológica 2010; 49: 378-381.

Dalton RSJ, Velineli R, Osborne ME, et al. A single centre experience of chemoradiotherapy for rectal cancer: Is there potential for nonoperative management? Colorectal Disease 2011; 14: 567-571.

Lim L, Chao M, Shapiro J, et al. Long-Term Outcomes of Patients with Localized Rectal Cancer Treated with Chemoradiation or Radiotherapy Alone Because of Medical Inoperability or Patient Refusal. Dis Colon Rectum 2007; 50: 2032-2039.

Neuman HB, Elkin EB, JG Guillem, et al. Treatment for Patients with Rectal Cancer and a Clinical Complete Response to Neoadjuvant Therapy: A Decision Analysis. Dis Colon Rectum 2009; 52 (5): 863-871.

Mignanelli ED, Campos-Lobato LF, Stocchi L, et al. Down staging after chemoradiotherapy for locally advanced rectal cancer: Is there more (tumor) than meets the eye? Diseases of the Colon & Rectum 2010; 53: 251-256.

Higgins KA, Willett CG, Czito BG. Nonoperative management of rectal cancer: Current perspectives. Clinical Colorectal Cancer 2010; 9(2): 83-88.

Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010; 11: 835-44.

Rullier E, Denost Q, Vendrely V, et al. Low Rectal Cancer: Classification and Standardization of Surgery. Dis Colon Rectum 2013; 56: 560-567.

Smith FM, Waldron D, Winter DC. Rectum-conserving surgery in the era of chemoradiotherapy. Br J Surg 2010; 97:1752-1764.

Nyasavajjala SM, Shaw AG, Khan AQ, et al. Neoadjuvant chemo-radiotherapy and rectal cancer: can the UK watch and wait with Brazil? Colorectal Disease 2010; 12: 33–36.

Fischkoff KN, Ruby JA, Guillem JG. Nonoperative approach to locally advance rectal cancer after neoadjuvant combined modality therapy: Challenges and opportunities from a surgical perspective. Clinical Colorectal Cancer 2011; 10(4): 291-7.

Martin ST, Heneghan MH, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. British Journal of Surgery 2012; 99: 918-928.

Publicado
2014-12-30
Cómo citar
Torres Mesa, P. A. (2014). Respuesta clínica completa postneoadyuvancia en cáncer de recto estadio III: observación o cirugía . Revista Colombiana De Gastroenterología, 29(4), 391-396. https://doi.org/10.22516/25007440.436
Sección
Revisión de tema